Fresenius Medical Care announced the launch of the first tranche of its initial EUR 1 billion share buyback program, a key component of its new capital allocation framework. This first tranche, valued at up to EUR 600 million, is planned for completion by April 30, 2026.
Helen Giza, CEO of Fresenius Medical Care, stated that this rapid implementation of the share buyback program underscores the company's goal of reigniting value creation for shareholders. This initiative allows shareholders to participate in the company's strength.
Martin Fischer, CFO, emphasized that regular share buybacks, alongside a consistent dividend policy, are integral to the new capital allocation framework. This move signals a strong commitment to enhancing shareholder value and optimizing the company's capital structure.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.